Scientific Excellence in Hearing Loss
Audion Therapeutics is a biopharmaceutical company that is dedicated to the discovery, development and commercialization of new treatments for hearing loss.
Our science and drug discovery platform originate from the Massachusetts Eye and Ear Infirmary (MEEI), a specialty hospital providing outstanding patient care for disorders of the eye, ear, nose, throat, head and neck with a leading international reputation in hearing loss research and a teaching partner of Harvard Medical School.
We have an experienced founder team that includes Albert Edge, Associate Professor at Harvard Medical School, Helmuth van Es (co-founder Galapagos and Effecta Pharma Ltd) and Rolf Jan Rutten. Audion’s technologies originated from Albert Edge’s research at the MEEI and are exclusively licensed to Audion.
We are approaching the development of new therapies by focusing on the regeneration of sensory hair cells in the inner ear, because these are lost in the vast majority of hearing loss cases. To achieve this we have a validated industrialized screening cascade and a critical path to identify, verify and develop new small molecule compounds. We have a broad patent portfolio that covers our drug discovery platform, screening cascades, molecular targets and new compounds.
We follow an active strategy aimed at expanding our pipeline with internally conceived as well as in licensed programs including e.g. non small molecule therapeutic modalities, protection and repair of Spiral Ganglia Neurons, and drug delivery. Key is tractability, solid IP protection and acceptable risk level and the feasibility of doing clinical PoC early on in development with minimal initial investment required. We invite researchers, TTOs and companies to contact us with ideas and intellectual properties that have the potential to become part of our strategy to bring medicines for hearing disorders to patients.
Audion Therapeutics BV recently moved into its new biology and pharmacology lab (as Audion LLC a wholly owned subsidiary of Audion Therapeutics BV) in the state of the art facilities of LabCentral in Cambridge, MA, USA (www.labcentral.org). LabCentral supports innovative biotechnology companies by providing a world-class environment and a fully functional laboratory within the Kendall Square innovation hub.